The trial production at the Brookshire facility is an important one for Waaree, with the Phase-1 manufacturing capacity of 1.6 gigawatts (GW) expected to be fully commissioned in the coming months ...
The press release emphasizes the company’s reliance on a third-party manufacturer for its clinical trial materials, which may signal a lack of in-house production capabilities. Forward-looking ...
The company plans to invest $1 billion in the Brookshire facility over the next four years, scaling production capacity from three gigawatts per year by the end of 2024 to five gigawatts by 2027.